WilmerHale Advises Auron Therapeutics in $48 million Series A Financing
On July 20, 2022, Auron Therapeutics, a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer,
announced the completion of its $48 million Series A financing round. Proceeds will be used to advance the lead program toward clinical development and drive additional programs into drug discovery. Funds will also be used to expand the proprietary, machine learning-based computational platform, AURigin, that is used to identify novel drug targets, and add personnel to support and accelerate research and development.
The WilmerHale deal team advising Auron Therapeutics was led by
Cynthia Mazareas and included
Elizabeth Brasher and
Ornella Ngounou.
